SARS-CoV-2 mRNA vaccines can stimulate antibody responses, decrease the risk of future coronavirus infections and appears to be a safe option for pregnant females and their fetuses.

This study systematically reviewed the latest evidences on SARS-CoV-2 vaccination for summarizing its safety, efficacy, and immunogenicity in pregnant females.

Databases (bioRxiv, Springer, MEDLINE, Proquest, ScienceDirect, Cochrane Library, medRxiv,)

and Registries (European Union Clinical Trial Registry, ClinicalTrials.gov, WHO Clinical Trial Registry) were systematically explored to find out research articles that concentrated on vaccination among pregnant females. A manual search of medRxiv and bioRxiv were also carried out.

Adverse events, infection rate, transplacental antibody transfer, and maternal antibody response were described.

In total, there were 13 observational studies and 48,039 pregnant females who received mRNA COVID-19 vaccines. Out of 13 studies, 3 studies examined infection rate, 6 studies assessed maternal antibody response, 7 studies assessed antibody transfer, 3 studies stated local adverse events, and 5 studies stated systemic adverse events. As per the available data, mRNA-based vaccines can aid in the prevention of future coronavirus disease. In pregnancy, no vaccine-associated harm was reported.

Headache, pain at the injection site, and fatigue were the most commonly encountered side effects. However, these noxious reactions were transient. Following the first dose of the vaccine, rapid antibody responses were noted. Following the booster, stronger antibody responses were noted and were found to be linked with improved transplacental antibody transfer. Longer intervals between initial vaccination dosage and delivery were also related to increased antibody fetal IgG and an improved antibody transfer ratio.

Owing to the safety profile, COVID-19 mRNA vaccines are encouraged for pregnant females. For higher robust fetal and maternal antibody responses, two doses of vaccine are suggested. Longer latency was related to greater fetal antibody responses. Additional investigation about its long-term impact on pregnancy is required.